China's SFDA and Brazil's Anvisa meet in Brasilia to strengthen collaboration
This article was originally published in Clinica
China's SFDA and Brazil's Anvisa healthcare regulatory agencies have met in Brasilia to further their collaboration in areas such as manufacturing inspections and information-sharing related to regulatory processes and standards.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.